{
    "hands_on_practices": [
        {
            "introduction": "Understanding the genetic basis of hemophilia is the first step in mastering its pathophysiology and clinical implications. This exercise delves into the fundamental principles of X-linked recessive inheritance, which governs the transmission of both hemophilia A and B. By applying Mendelian genetics to a classic scenario involving a carrier mother and an unaffected father, you will calculate the precise probabilities of offspring being affected or becoming carriers, a skill that is the cornerstone of genetic counseling .",
            "id": "4379842",
            "problem": "A woman is heterozygous for a pathogenic variant in the coagulation factor VIII gene ($F8$) and, in a separate scenario, heterozygous for a pathogenic variant in the coagulation factor IX gene ($F9$). The coagulation factor VIII gene ($F8$) is located at $Xq28$, and the coagulation factor IX gene ($F9$) is located at $Xq27.1$. Both hemophilia A (due to $F8$ deficiency) and hemophilia B (due to $F9$ deficiency) follow an X-linked recessive (XLR) inheritance pattern. The father in both scenarios is clinically unaffected and genotypically normal. Using the foundational principles of Mendelian inheritance (random segregation of alleles) and sex chromosome transmission in humans, derive the conditional probabilities that, when the mother is a known carrier, a son will be affected and a daughter will be a carrier for hemophilia A, and repeat the derivation for hemophilia B. Assume no new mutations, equal viability of gametes, and that lyonization (X-chromosome inactivation) does not cause clinical disease in heterozygous females under these conditions. Express your final four conditional probabilities in a single row matrix using fraction form, in the order: hemophilia A son affected, hemophilia A daughter carrier, hemophilia B son affected, hemophilia B daughter carrier. No rounding is required, and no units are involved in the final answer.",
            "solution": "The problem statement is deemed valid. It is scientifically grounded in the principles of human genetics, well-posed with sufficient information and clear assumptions, and stated objectively. The analysis will proceed by applying the foundational principles of Mendelian genetics to the specified X-linked recessive inheritance patterns.\n\nLet us define the alleles and genotypes involved in each scenario. The inheritance of sex chromosomes dictates that a female parent contributes an $X$ chromosome to every offspring, while a male parent contributes an $X$ chromosome to daughters and a $Y$ chromosome to sons.\n\n**Scenario 1: Hemophilia A (due to pathogenic variant in the $F8$ gene)**\n\nThe $F8$ gene is located on the $X$ chromosome. We will denote the $X$ chromosome carrying the normal (wild-type) allele as $X^A$ and the $X$ chromosome carrying the pathogenic (hemophilia-causing) recessive allele as $X^a$.\n\nThe problem states the parental genotypes are as follows:\n- Mother is a heterozygous carrier: Her genotype is $X^A X^a$.\n- Father is genotypically normal: His genotype is $X^A Y$.\n\nAccording to the principle of random segregation, the mother produces two types of gametes (ova) with equal probability: $X^A$ with probability $P(X^A_{mother}) = \\frac{1}{2}$ and $X^a$ with probability $P(X^a_{mother}) = \\frac{1}{2}$. The father produces two types of gametes (sperm) with equal probability: $X^A$ with probability $P(X^A_{father}) = \\frac{1}{2}$ and $Y$ with probability $P(Y_{father}) = \\frac{1}{2}$.\n\nWe can construct a Punnett square to determine the probabilities of the possible genotypes of the offspring. The total probability of any given offspring genotype is the product of the probabilities of the constituent gametes, assuming independent segregation.\n\nThe possible genotypes and their associated probabilities are:\n1.  Daughter, homozygous normal: $X^A X^A$. This results from the fusion of an $X^A$ ovum and an $X^A$ sperm. The probability is $P(X^A X^A) = P(X^A_{mother}) \\times P(X^A_{father}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$.\n2.  Daughter, heterozygous carrier: $X^A X^a$. This results from the fusion of an $X^a$ ovum and an $X^A$ sperm. The probability is $P(X^A X^a) = P(X^a_{mother}) \\times P(X^A_{father}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$.\n3.  Son, genotypically normal: $X^A Y$. This results from the fusion of an $X^A$ ovum and a $Y$ sperm. The probability is $P(X^A Y) = P(X^A_{mother}) \\times P(Y_{father}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$.\n4.  Son, affected with hemophilia A: $X^a Y$. This results from the fusion of an $X^a$ ovum and a $Y$ sperm. The probability is $P(X^a Y) = P(X^a_{mother}) \\times P(Y_{father}) = \\frac{1}{2} \\times \\frac{1}{2} = \\frac{1}{4}$.\n\nThe problem requires the conditional probabilities for a given sex.\nThe probability of having a son is $P(\\text{son}) = P(X^A Y) + P(X^a Y) = \\frac{1}{4} + \\frac{1}{4} = \\frac{1}{2}$.\nThe probability of having a daughter is $P(\\text{daughter}) = P(X^A X^A) + P(X^A X^a) = \\frac{1}{4} + \\frac{1}{4} = \\frac{1}{2}$.\n\n- **Conditional probability that a son will be affected:**\nThis is the probability of the genotype $X^a Y$ given that the offspring is a son.\n$P(\\text{son is affected}) = P(X^a Y | \\text{son}) = \\frac{P(X^a Y \\cap \\text{son})}{P(\\text{son})} = \\frac{P(X^a Y)}{P(\\text{son})} = \\frac{1/4}{1/2} = \\frac{1}{2}$.\nA more direct derivation recognizes that a son must inherit his $X$ chromosome from his mother. Since the mother is $X^A X^a$, there is a $\\frac{1}{2}$ probability of her passing the $X^a$ allele to her son, thus making him affected.\n\n- **Conditional probability that a daughter will be a carrier:**\nThis is the probability of the genotype $X^A X^a$ given that the offspring is a daughter.\n$P(\\text{daughter is carrier}) = P(X^A X^a | \\text{daughter}) = \\frac{P(X^A X^a \\cap \\text{daughter})}{P(\\text{daughter})} = \\frac{P(X^A X^a)}{P(\\text{daughter})} = \\frac{1/4}{1/2} = \\frac{1}{2}$.\nA daughter inherits one $X$ chromosome from her mother and one from her father. The father can only provide the $X^A$ allele. To be a carrier ($X^A X^a$), she must inherit the $X^a$ allele from her mother, which occurs with a probability of $\\frac{1}{2}$.\n\n**Scenario 2: Hemophilia B (due to pathogenic variant in the $F9$ gene)**\n\nThe problem specifies that hemophilia B also follows an X-linked recessive inheritance pattern. The gene locus, $Xq27.1$ for $F9$ versus $Xq28$ for $F8$, is noted, but because the scenarios are treated separately, this information is contextual and does not alter the fundamental transmission genetics. The mathematical derivation is structurally identical to that for hemophilia A.\n\nLet us denote the $X$ chromosome with the normal $F9$ allele as $X^B$ and the one with the pathogenic allele as $X^b$.\n- Mother's genotype: $X^B X^b$.\n- Father's genotype: $X^B Y$.\n\nFollowing the exact same logic as in Scenario 1:\n- Gamete probabilities from the mother are $P(X^B_{mother}) = \\frac{1}{2}$ and $P(X^b_{mother}) = \\frac{1}{2}$.\n- Gamete probabilities from the father are $P(X^B_{father}) = \\frac{1}{2}$ and $P(Y_{father}) = \\frac{1}{2}$.\n\n- **Conditional probability that a son will be affected:**\nA son receives a $Y$ chromosome from the father and one of the mother's two $X$ chromosomes. The probability of inheriting the $X^b$ allele from his mother is $\\frac{1}{2}$.\n\n- **Conditional probability that a daughter will be a carrier:**\nA daughter receives the father's $X^B$ chromosome. To be a carrier, she must inherit the $X^b$ allele from her mother. The probability of this event is $\\frac{1}{2}$.\n\nTherefore, all four requested probabilities are $\\frac{1}{2}$.\n\nThe final answer requires the probabilities in the following order:\n1.  Conditional probability that a son will be affected with hemophilia A: $\\frac{1}{2}$.\n2.  Conditional probability that a daughter will be a carrier for hemophilia A: $\\frac{1}{2}$.\n3.  Conditional probability that a son will be affected with hemophilia B: $\\frac{1}{2}$.\n4.  Conditional probability that a daughter will be a carrier for hemophilia B: $\\frac{1}{2}$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n\\frac{1}{2}  \\frac{1}{2}  \\frac{1}{2}  \\frac{1}{2}\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Moving from genetics to diagnosis, a key laboratory finding in hemophilia is a prolonged activated partial thromboplastin time (APTT). However, this finding alone is not specific. This practice places you in the role of a clinical pathologist tasked with interpreting a crucial diagnostic test: the APTT mixing study. You will learn to quantitatively analyze mixing study data to distinguish between a congenital factor deficiency, which corrects with normal plasma, and acquired hemophilia, where an inhibitor prevents correction, a distinction that fundamentally alters the treatment approach .",
            "id": "4789743",
            "problem": "A hematology laboratory is asked to differentiate a congenital Factor VIII deficiency (Hemophilia A) from Acquired Hemophilia A using the activated partial thromboplastin time (APTT) mixing study. The activated partial thromboplastin time measures the integrity of the intrinsic and common pathways of coagulation and is prolonged when clotting factor levels such as Factor VIII are reduced or inhibited. In a standard $1:1$ mixing study, equal volumes of patient plasma and normal pooled plasma are combined; the mixture’s APTT is measured immediately at $t=0$ and after incubation at $37^{\\circ}\\text{C}$ for $2$ hours. Conceptually, “correction” is the fraction of the abnormal prolongation (above normal) that is eliminated by mixing with normal plasma.\n\nYou are given the following APTT data obtained on the same reagent system with a normal control APTT of $30.0 \\ \\text{s}$:\n\n- Patient $X$ (suspected congenital Hemophilia A): patient APTT $=74.0 \\ \\text{s}$; $1:1$ mix APTT at $t=0$ $=33.8 \\ \\text{s}$; $1:1$ mix APTT after $2$ hours at $37^{\\circ}\\text{C}$ $=34.6 \\ \\text{s}$.\n- Patient $Y$ (suspected Acquired Hemophilia A with a time-dependent inhibitor): patient APTT $=92.0 \\ \\text{s}$; $1:1$ mix APTT at $t=0$ $=54.0 \\ \\text{s}$; $1:1$ mix APTT after $2$ hours at $37^{\\circ}\\text{C}$ $=86.0 \\ \\text{s}$.\n\nFrom first principles, compute for each patient the correction fraction at $t=0$ and after $2$ hours as a dimensionless decimal, defined as the fraction of the abnormal prolongation above normal that is eliminated by mixing. Then, based on these values, interpret whether an inhibitor is present in each case by reasoning from the behavior over time.\n\nRound each reported correction fraction to four significant figures. Express the final numerical values as decimal fractions with no units. Provide your final numerical results in the order: Patient $X$ at $t=0$, Patient $X$ at $2$ hours, Patient $Y$ at $t=0$, Patient $Y$ at $2$ hours. The interpretation should be reasoned in words but the final answer must be only the numerical values as specified.",
            "solution": "The problem statement has been critically validated and is deemed to be valid. It is scientifically grounded in established principles of hematology and coagulation testing, well-posed with a clear definition and sufficient data for a unique solution, and objective in its language.\n\nThe core of this problem is to distinguish between a clotting factor deficiency and the presence of a factor inhibitor using an activated partial thromboplastin time (APTT) mixing study. The problem provides a quantitative definition for \"correction,\" which we will use to analyze the provided data.\n\nLet us define the relevant variables:\n- $APTT_{norm}$ is the APTT of the normal control plasma.\n- $APTT_{pat}$ is the APTT of the patient's plasma.\n- $APTT_{mix}(t)$ is the APTT of the $1:1$ mixture of patient and normal plasma, measured at time $t$.\n\nThe abnormal prolongation of the APTT in the patient's sample is the difference between the patient's APTT and the normal APTT:\n$$ \\Delta_{abnormal} = APTT_{pat} - APTT_{norm} $$\nThis value represents the total prolongation that mixing with normal plasma aims to correct.\n\nAfter mixing, any remaining prolongation in the mixture is given by:\n$$ \\Delta_{mix}(t) = APTT_{mix}(t) - APTT_{norm} $$\n\nThe total amount of correction achieved by mixing is the reduction in the prolongation:\n$$ \\text{Correction Amount} = \\Delta_{abnormal} - \\Delta_{mix}(t) = (APTT_{pat} - APTT_{norm}) - (APTT_{mix}(t) - APTT_{norm}) = APTT_{pat} - APTT_{mix}(t) $$\n\nThe problem defines the correction fraction, which we denote as $C(t)$, as the fraction of the abnormal prolongation that is eliminated. This is formulated as:\n$$ C(t) = \\frac{\\text{Correction Amount}}{\\Delta_{abnormal}} = \\frac{APTT_{pat} - APTT_{mix}(t)}{APTT_{pat} - APTT_{norm}} $$\n\nWe are given the normal control APTT: $APTT_{norm} = 30.0 \\ \\text{s}$.\n\nNow, we will apply this formula to the data for Patient $X$ and Patient $Y$.\n\nFor Patient $X$:\n- Patient APTT: $APTT_{pat,X} = 74.0 \\ \\text{s}$\n- Mix APTT at $t=0$: $APTT_{mix, X}(0) = 33.8 \\ \\text{s}$\n- Mix APTT at $t=2 \\ \\text{hr}$: $APTT_{mix, X}(2) = 34.6 \\ \\text{s}$\n\nThe correction fraction for Patient $X$ at $t=0$ is:\n$$ C_X(0) = \\frac{APTT_{pat,X} - APTT_{mix, X}(0)}{APTT_{pat,X} - APTT_{norm}} = \\frac{74.0 - 33.8}{74.0 - 30.0} = \\frac{40.2}{44.0} \\approx 0.913636... $$\nRounded to four significant figures, $C_X(0) = 0.9136$.\n\nThe correction fraction for Patient $X$ at $t=2 \\ \\text{hours}$ is:\n$$ C_X(2) = \\frac{APTT_{pat,X} - APTT_{mix, X}(2)}{APTT_{pat,X} - APTT_{norm}} = \\frac{74.0 - 34.6}{74.0 - 30.0} = \\frac{39.4}{44.0} \\approx 0.895454... $$\nRounded to four significant figures, $C_X(2) = 0.8955$.\n\nInterpretation for Patient $X$: The correction fraction is very high at both $t=0$ ($0.9136$) and after $2$ hours of incubation ($0.8955$). This indicates that mixing the patient's plasma with normal plasma, which contains approximately $100\\%$ Factor VIII, successfully brings the APTT back to near-normal levels (a mixture with $\\approx 50\\%$ Factor VIII is sufficient for a normal APTT). The correction is stable over the $2$-hour incubation period. This pattern is characteristic of a simple factor deficiency without the presence of an inhibitor. The result strongly supports the diagnosis of congenital Hemophilia A.\n\nFor Patient $Y$:\n- Patient APTT: $APTT_{pat,Y} = 92.0 \\ \\text{s}$\n- Mix APTT at $t=0$: $APTT_{mix, Y}(0) = 54.0 \\ \\text{s}$\n- Mix APTT at $t=2 \\ \\text{hr}$: $APTT_{mix, Y}(2) = 86.0 \\ \\text{s}$\n\nThe correction fraction for Patient $Y$ at $t=0$ is:\n$$ C_Y(0) = \\frac{APTT_{pat,Y} - APTT_{mix, Y}(0)}{APTT_{pat,Y} - APTT_{norm}} = \\frac{92.0 - 54.0}{92.0 - 30.0} = \\frac{38.0}{62.0} \\approx 0.612903... $$\nRounded to four significant figures, $C_Y(0) = 0.6129$.\n\nThe correction fraction for Patient $Y$ at $t=2 \\ \\text{hours}$ is:\n$$ C_Y(2) = \\frac{APTT_{pat,Y} - APTT_{mix, Y}(2)}{APTT_{pat,Y} - APTT_{norm}} = \\frac{92.0 - 86.0}{92.0 - 30.0} = \\frac{6.0}{62.0} \\approx 0.096774... $$\nRounded to four significant figures, $C_Y(2) = 0.09677$.\n\nInterpretation for Patient $Y$: There is partial correction at $t=0$ ($C_Y(0) = 0.6129$), as the mix APTT of $54.0 \\ \\text{s}$ is lower than the patient's $92.0 \\ \\text{s}$ but still significantly prolonged compared to the normal $30.0 \\ \\text{s}$. However, after incubation for $2$ hours at $37^{\\circ}\\text{C}$, the correction is almost completely lost, with the correction fraction dropping to a very low value ($C_Y(2) = 0.09677$). The APTT of the mix has reverted to being nearly as prolonged as the original patient sample. This behavior—initial partial correction followed by a loss of correction over time and with incubation—is the hallmark of a time- and temperature-dependent inhibitor. The inhibitor (an antibody to Factor VIII) in the patient's plasma has neutralized the Factor VIII supplied by the normal plasma. This pattern is characteristic of Acquired Hemophilia A.\n\nThe final numerical values are calculated as requested.",
            "answer": "$$ \\boxed{ \\begin{pmatrix} 0.9136  0.8955  0.6129  0.09677 \\end{pmatrix} } $$"
        },
        {
            "introduction": "The cornerstone of hemophilia management is replacing the deficient clotting factor, but effective treatment requires a sophisticated, quantitative approach beyond a simple single dose. This advanced exercise simulates the real-world clinical challenge of planning a perioperative factor replacement regimen for a patient undergoing major surgery. You will integrate key pharmacokinetic principles, including factor half-life ($t_{1/2}$) and recovery, to calculate a sequence of doses that maintains the patient's factor levels within a specific therapeutic window over several days .",
            "id": "4379839",
            "problem": "A patient with severe hemophilia A (Factor VIII deficiency) is scheduled for a major orthopedic procedure. Assume the following scientifically grounded facts and definitions as the starting base: (i) in the absence of inhibitors, the plasma concentration of an infused coagulation factor decays according to one-compartment first-order kinetics, where the definition of half-life implies that a level after a time interval $\\Delta t$ is given by the previous level multiplied by $2^{-\\Delta t/t_{1/2}}$; (ii) “recovery” is defined as the instantaneous increment in plasma level in international units per deciliter (IU/dL) produced per international unit per kilogram (IU/kg) infused, so that an intravenous bolus dose of $D$ IU/kg produces an immediate level increase of $R \\times D$ IU/dL; (iii) there is negligible endogenous production during the perioperative window; and (iv) there are no inhibitors and no additional clearance beyond the pharmacokinetic decay.\n\nFor coagulation Factor VIII (FVIII), take the half-life $t_{1/2}$ to be $12$ hours, and the recovery $R$ to be $2$ IU/dL per IU/kg. The baseline FVIII level is $0$ IU/dL. A clinically reasonable perioperative target for major surgery is to achieve trough FVIII levels of at least $50$ IU/dL during the first $24$ hours (from $0$ to $24$ hours post-dose) and at least $30$ IU/dL from $24$ to $72$ hours. You will administer bolus doses at times $0$, $12$, $24$, $36$, $48$, and $60$ hours.\n\nUsing only the fundamental definitions above, determine the minimal bolus doses at each scheduled time, in IU/kg, such that the trough (the level immediately before the next scheduled dose) meets the target for each interval. Express your answer as a single row matrix containing six entries corresponding to dosing times $0$, $12$, $24$, $36$, $48$, and $60$ hours, respectively. Round your entries to three significant figures. Do not include units in the matrix; all doses are in IU/kg.",
            "solution": "The problem is evaluated for validity prior to attempting a solution.\n\n### Step 1: Extract Givens\n- **Pharmacokinetic Model**: One-compartment first-order kinetics. The plasma factor level $L(t)$ at time $t$ after an interval $\\Delta t$ from time $t_0$ is given by $L(t_0 + \\Delta t) = L(t_0) \\times 2^{-\\Delta t/t_{1/2}}$.\n- **Recovery ($R$)**: The instantaneous increment in plasma level (in IU/dL) per infused dose (in IU/kg). An intravenous bolus dose of $D$ IU/kg produces an immediate level increase of $R \\times D$ IU/dL.\n- **Endogenous Production**: Negligible during the perioperative window.\n- **Inhibitors/Clearance**: No inhibitors or additional clearance mechanisms beyond the specified pharmacokinetic decay.\n- **Factor VIII Half-life ($t_{1/2}$)**: $12$ hours.\n- **Factor VIII Recovery ($R$)**: $2$ IU/dL per IU/kg.\n- **Baseline Level**: The initial FVIII level at time $t=0$ is $0$ IU/dL.\n- **Target Trough Levels**:\n  - At least $50$ IU/dL for the interval from $0$ to $24$ hours.\n  - At least $30$ IU/dL for the interval from $24$ to $72$ hours.\n- **Dosing Schedule**: Bolus doses administered at times $t = 0, 12, 24, 36, 48, 60$ hours.\n- **Objective**: Determine the minimal bolus doses at each scheduled time point.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is grounded in standard pharmacokinetic principles. The one-compartment model is a widely used simplification for drug concentration modeling. The values for FVIII half-life ($12$ hours) and recovery ($2$ IU/dL per IU/kg) are consistent with accepted clinical data. The target levels are also clinically relevant for major surgery in hemophilia A patients.\n- **Well-Posed**: The problem is well-posed. It provides all necessary parameters and constraints. The requirement for *minimal* doses ensures that a unique solution exists, as it implies setting the trough levels to the exact minimum required value at each step.\n- **Objective**: The problem is stated using precise, objective scientific and mathematical language. There are no subjective or ambiguous terms.\n\n### Step 3: Verdict and Action\nThe problem is scientifically sound, well-posed, and objective. It contains no invalidating flaws. Therefore, it is deemed **valid**, and a solution will be provided.\n\n### Solution Derivation\nLet $L(t)$ be the plasma FVIII level in IU/dL at time $t$ in hours. Let $L(t^-)$ be the level just before a dose at time $t$ (the trough level), and $L(t^+)$ be the level just after the dose (the peak level). Let $D_t$ be the dose in IU/kg administered at time $t$.\n\nAccording to the given definitions:\nThe level increase from a dose $D_t$ is:\n$$L(t^+) = L(t^-) + R \\cdot D_t$$\n\nThe level decay over a time interval $\\Delta t$ is:\n$$L(t + \\Delta t) = L(t) \\cdot 2^{-\\frac{\\Delta t}{t_{1/2}}}$$\n\nThe given parameters are $R = 2$ IU/dL per IU/kg and $t_{1/2} = 12$ hours. The dosing interval is $\\Delta t = 12$ hours. Therefore, the decay factor over one dosing interval is:\n$$2^{-\\frac{\\Delta t}{t_{1/2}}} = 2^{-\\frac{12}{12}} = 2^{-1} = 0.5$$\n\nThis means the FVIII level halves every $12$ hours. The trough level at the end of an interval, $L((t+\\Delta t)^-)$, is half of the peak level at the start of the interval, $L(t^+)$:\n$$L((t+\\Delta t)^-) = L(t^+) \\cdot 0.5 \\implies L(t^+) = 2 \\cdot L((t+\\Delta t)^-)$$\n\nTo find the minimal dose $D_t$, we set the subsequent trough level, $L((t+\\Delta t)^-)$, to its minimum required target value, which we denote $L_{\\text{target}}$.\nThe peak level required at time $t$ is $L(t^+) = 2 \\cdot L_{\\text{target}}$.\nThe dose $D_t$ is calculated by finding the required increase in level, $L(t^+) - L(t^-)$, and dividing by the recovery $R$:\n$$D_t = \\frac{L(t^+) - L(t^-)}{R} = \\frac{2 \\cdot L_{\\text{target}} - L(t^-)}{R}$$\n\nWe can now calculate the doses sequentially.\n\n**1. Dose at $t=0$ ($D_0$):**\n- The trough level before the first dose is the baseline: $L(0^-) = 0$ IU/dL.\n- The target trough for the first interval ($0-24$ hours) is $\\ge 50$ IU/dL. This applies to the trough at $t=12$ hours. So, $L(12^-)_{\\text{target}} = 50$ IU/dL.\n- The required peak level at $t=0$ is $L(0^+) = 2 \\cdot L(12^-)_{\\text{target}} = 2 \\cdot 50 = 100$ IU/dL.\n- The dose is:\n$$D_0 = \\frac{L(0^+) - L(0^-)}{R} = \\frac{100 - 0}{2} = 50 \\text{ IU/kg}$$\nThe trough level at $t=12$ will be $L(12^-) = L(0^+) \\cdot 0.5 = 100 \\cdot 0.5 = 50$ IU/dL.\n\n**2. Dose at $t=12$ ($D_{12}$):**\n- The trough level at $t=12$ is $L(12^-) = 50$ IU/dL.\n- The target trough for this interval (ending at $t=24$) is still $\\ge 50$ IU/dL. So, $L(24^-)_{\\text{target}} = 50$ IU/dL.\n- The required peak level at $t=12$ is $L(12^+) = 2 \\cdot L(24^-)_{\\text{target}} = 2 \\cdot 50 = 100$ IU/dL.\n- The dose is:\n$$D_{12} = \\frac{L(12^+) - L(12^-)}{R} = \\frac{100 - 50}{2} = 25 \\text{ IU/kg}$$\nThe trough level at $t=24$ will be $L(24^-) = L(12^+) \\cdot 0.5 = 100 \\cdot 0.5 = 50$ IU/dL.\n\n**3. Dose at $t=24$ ($D_{24}$):**\n- The trough level at $t=24$ is $L(24^-) = 50$ IU/dL.\n- The target trough level changes for the interval starting at $t=24$ hours to $\\ge 30$ IU/dL. This applies to the trough at $t=36$. So, $L(36^-)_{\\text{target}} = 30$ IU/dL.\n- The required peak level at $t=24$ is $L(24^+) = 2 \\cdot L(36^-)_{\\text{target}} = 2 \\cdot 30 = 60$ IU/dL.\n- The dose is:\n$$D_{24} = \\frac{L(24^+) - L(24^-)}{R} = \\frac{60 - 50}{2} = 5 \\text{ IU/kg}$$\nThe trough level at $t=36$ will be $L(36^-) = L(24^+) \\cdot 0.5 = 60 \\cdot 0.5 = 30$ IU/dL.\n\n**4. Dose at $t=36$ ($D_{36}$):**\n- The trough level at $t=36$ is $L(36^-) = 30$ IU/dL.\n- The target trough for this interval (ending at $t=48$) is $\\ge 30$ IU/dL. So, $L(48^-)_{\\text{target}} = 30$ IU/dL.\n- The required peak level at $t=36$ is $L(36^+) = 2 \\cdot L(48^-)_{\\text{target}} = 2 \\cdot 30 = 60$ IU/dL.\n- The dose is:\n$$D_{36} = \\frac{L(36^+) - L(36^-)}{R} = \\frac{60 - 30}{2} = 15 \\text{ IU/kg}$$\nThe trough level at $t=48$ will be $L(48^-) = L(36^+) \\cdot 0.5 = 60 \\cdot 0.5 = 30$ IU/dL.\n\n**5. Dose at $t=48$ ($D_{48}$):**\n- The trough level at $t=48$ is $L(48^-) = 30$ IU/dL.\n- The target trough for this interval (ending at $t=60$) is $\\ge 30$ IU/dL. So, $L(60^-)_{\\text{target}} = 30$ IU/dL.\n- The required peak level at $t=48$ is $L(48^+) = 2 \\cdot L(60^-)_{\\text{target}} = 2 \\cdot 30 = 60$ IU/dL.\n- The dose is:\n$$D_{48} = \\frac{L(48^+) - L(48^-)}{R} = \\frac{60 - 30}{2} = 15 \\text{ IU/kg}$$\nThe trough level at $t=60$ will be $L(60^-) = L(48^+) \\cdot 0.5 = 60 \\cdot 0.5 = 30$ IU/dL.\n\n**6. Dose at $t=60$ ($D_{60}$):**\n- The trough level at $t=60$ is $L(60^-) = 30$ IU/dL.\n- The target trough for this interval (ending at $t=72$) is $\\ge 30$ IU/dL. So, $L(72^-)_{\\text{target}} = 30$ IU/dL.\n- The required peak level at $t=60$ is $L(60^+) = 2 \\cdot L(72^-)_{\\text{target}} = 2 \\cdot 30 = 60$ IU/dL.\n- The dose is:\n$$D_{60} = \\frac{L(60^+) - L(60^-)}{R} = \\frac{60 - 30}{2} = 15 \\text{ IU/kg}$$\n\nThe calculated minimal doses are $50$, $25$, $5$, $15$, $15$, and $15$ IU/kg. Rounding these to three significant figures gives $50.0$, $25.0$, $5.00$, $15.0$, $15.0$, and $15.0$.\n\nThese doses are compiled into a single row matrix as requested.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n50.0  25.0  5.00  15.0  15.0  15.0\n\\end{pmatrix}\n}\n$$"
        }
    ]
}